RUNX1T1 and acute myeloid leukemia: In conclusion, we demonstrate that BRCC3 mutations lead to altered ubiquitination of its substrates and cytokine release which cooperates with AML1-ETO to induce AML and sensitizes the leukemic cells to cytotoxic chemotherapy.